This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Simeoni, M. Articles by Rocchetti, M. Search for Related Content PubMed PubMed Citation Articles by Simeoni, M. Articles by Rocchetti, M.

Predictive Pharmacokinetic-Pharmacodynamic Modeling of Tumor Growth Kinetics in Xenograft Models after Administration of Anticancer Agents

¹ Dipartimento di Informatica e Sistemistica, University of Pavia, Pavia, and ² Pharmacia Italia S.p.A., Nerviano (MI), Italy

The available mathematical models describing tumor growth and the effect of anticancer treatments on tumors in animals are of limited use within the drug industry. A simple and effective model would allow applying quantitative thinking to the preclinical development of oncology drugs. In this article, a minimal pharmacokinetic-pharmacodynamic model is presented, based on a system of ordinary differential equations that link the dosing regimen of a compound to the tumor growth in animal models. The growth of tumors in nontreated animals is described by an exponential growth followed by a linear growth. In treated animals, the tumor growth rate is decreased by a factor proportional to both drug concentration and number of proliferating tumor cells. A transit compartmental system is used to model the process of cell death, which occurs at later times. The parameters of the pharmacodynamic model are related to the growth characteristics of the tumor, to the drug potency, and to the kinetics of the tumor cell death. Therefore, such parameters can be used for ranking compounds based on their potency and for evaluating potential differences in the tumor cell death process. The model was extensively tested on discovery candidates and known anticancer drugs. It fitted well the experimental data, providing reliable parameter estimates. On the basis of the parameters estimated in a first experiment, the model successfully predicted the response of tumors exposed to drugs given at different dose levels and/or schedules. It is, thus, possible to use the model prospectively, optimizing the design of new experiments.

This article has been cited by other articles:

				P. Ubezio, M. Lupi, D. Branduardi, P. Cappella, E. Cavallini, V. Colombo, G. Matera, C. Natoli, D. Tomasoni, and M. D'Incalci Quantitative Assessment of the Complex Dynamics of G1, S, and G2-M Checkpoint Activities Cancer Res., June 15, 2009; 69(12): 5234 - 5240. [Abstract] [Full Text] [PDF]

				S. Yamazaki, J. Skaptason, D. Romero, J. H. Lee, H. Y. Zou, J. G. Christensen, J. R. Koup, B. J. Smith, and T. Koudriakova Pharmacokinetic-Pharmacodynamic Modeling of Biomarker Response and Tumor Growth Inhibition to an Orally Available cMet Kinase Inhibitor in Human Tumor Xenograft Mouse Models Drug Metab. Dispos., July 1, 2008; 36(7): 1267 - 1274. [Abstract] [Full Text] [PDF]

				M. Bergstrom, A. Monazzam, P. Razifar, S. Ide, R. Josephsson, and B. Langstrom Modeling Spheroid Growth, PET Tracer Uptake, and Treatment Effects of the Hsp90 Inhibitor NVP-AUY922 J. Nucl. Med., July 1, 2008; 49(7): 1204 - 1210. [Abstract] [Full Text] [PDF]

				L.-S. Tham, L. Wang, R. A. Soo, S.-C. Lee, H.-S. Lee, W.-P. Yong, B.-C. Goh, and N. H.G. Holford A Pharmacodynamic Model for the Time Course of Tumor Shrinkage by Gemcitabine + Carboplatin in Non-Small Cell Lung Cancer Patients Clin. Cancer Res., July 1, 2008; 14(13): 4213 - 4218. [Abstract] [Full Text] [PDF]

				S. Wang, P. Guo, X. Wang, Q. Zhou, and J. M. Gallo Preclinical pharmacokinetic/pharmacodynamic models of gefitinib and the design of equivalent dosing regimens in EGFR wild-type and mutant tumor models Mol. Cancer Ther., February 1, 2008; 7(2): 407 - 417. [Abstract] [Full Text] [PDF]

				R. Altenburger, M. Schmitt-Jansen, and J. Riedl Bioassays with Unicellular Algae: Deviations from Exponential Growth and Its Implications for Toxicity Test Results J. Environ. Qual., January 4, 2008; 37(1): 16 - 21. [Abstract] [Full Text] [PDF]

				P. Carpinelli, R. Ceruti, M. L. Giorgini, P. Cappella, L. Gianellini, V. Croci, A. Degrassi, G. Texido, M. Rocchetti, P. Vianello, et al. PHA-739358, a potent inhibitor of Aurora kinases with a selective target inhibition profile relevant to cancer Mol. Cancer Ther., December 1, 2007; 6(12): 3158 - 3168. [Abstract] [Full Text] [PDF]

				C. Soncini, P. Carpinelli, L. Gianellini, D. Fancelli, P. Vianello, L. Rusconi, P. Storici, P. Zugnoni, E. Pesenti, V. Croci, et al. PHA-680632, a Novel Aurora Kinase Inhibitor with Potent Antitumoral Activity. Clin. Cancer Res., July 1, 2006; 12(13): 4080 - 4089. [Abstract] [Full Text] [PDF]

				M. Zhu and M. Pfister Optimizing Benefit/Risk Profiles of New Oncology Agents With Modeling and Simulation Am. Assoc. Cancer Res. Educ. Book, April 1, 2006; 2006(1): 45 - 49. [Full Text] [PDF]